Company profile / ANTHEM

Anthem Biosciences

Other · 1 quarter tracked · source-linked performance and management context.

Research layer active
PositiveDelivery assessment incompleteLatest record q3-fy26

Latest revenue

₹423 Cr

verified financial record

Quarters tracked

1

source records in the directory

Delivery assessment

Unscored

No scored management commitments are present yet.

Call date

2026-01-15

latest available source date

Signal trajectory

1 actual quarter
PAT (₹ Cr)PositiveWatchNegative
1 actual records
Actual quarterly PAT (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q3 FY26: 93 · Positive source sentiment · 2026-01-15Q3 FY269393
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Current read

Unscored

No scored management commitments are present yet.

Latest source read

What changed this quarter?

Open quarter read

Anthem Biosciences reported Q3 FY26 consolidated revenue of 423 crore and EBITDA of 191 crore (41.8% margin), with PAT at 93 crore (20.3% margin). The 9-month revenue reached 1,513 crore, driven by CRDMO (1,260 crore) and specialty ingredients (254 crore). EBITDA margin improved to 41.5% for 9M, aided by backward integration and cost control. Management noted a temporary slowdown due to customer destocking and geopolitical uncertainty, but expects a strong Q4 and FY27 recovery. Guidance for FY26: revenue growth of 15-16% and EBITDA/PAT growth above 20%. Key risks include lumpy business nature and potential delays in new product ramp-up.

Colored figures compare against the previous available record. Hover or focus one for the comparison.

Signal

Positive

Revenue

₹423 Cr

Source date

2026-01-15

Across the record

Quarter history.

1 source records

History modules

Follow the numbers and themes.

Revenue history PAT history Margin trend Guidance tracker Bear-case history Language trends FY26 summary